TORONTO & AUSTIN, TEXAS, April 2 /CNW/ - Affinium Pharmaceuticals, Inc.,
a privately held developer of a novel class of highly potent oral
antibacterial therapeutics announces the addition of Dr. Barry Hafkin as its
Chief Medical Officer. Dr. Hafkin will lead Affinium's clinical development
program and establish Affinium's new regulatory team based in Austin Texas.
An accomplished pharmaceutical executive, Dr. Hafkin brings more than 16
years of experience in the pharmaceutical and biotechnology industries to
Affinium. As Senior Director of Antibacterial Development and later the
therapeutic area leader at Pharmacia, Dr. Hafkin led the successful global
development and registration of Zyvox. Zyvox is an antibiotic specifically
designed to address some of the most important problems in treating multiple
drug resistant bacterial infections. The product now marketed by Pfizer has
been widely embraced by the medical communities throughout the world; sales
for Zyvox are estimated to be $900 million and growing by 30% per year.
"I am very excited to be leading the development team at Affinium as we
prepare our clinical candidate for its Phase 1 trial this year," commented Dr.
Hafkin. "The increasing prevalence of staphylococcal infections such as
methicillin-resistant S. aureus (MRSA) in hospitals and the community means
that there is an urgent need for new classes of potent antibiotics like those
being developed at Affinium."
"We are very pleased to have Dr. Hafkin join Affinium as the company
enters its next phase of drug development," noted Dr. Stuart Collinson,
Chairman of the Board of Directors. "Dr. Hafkin's experience at developing new
oral and intravenous antibiotics makes him uniquely qualified to lead
Affinium's clinical program."
A graduate of the University of Texas Medical School at San Antonio,
Texas, Dr. Hafkin completed his Postdoctoral Fellow in Infectious Disease at
Stanford University Medical Center, Stanford Medical School, Palo Alto,
California. Prior to coming to Affinium Dr. Hafkin served as President and CEO
of Cumbre Pharmaceuticals, Inc, of Dallas, Texas, and prior to that as Senior
Vice President and Chief Scientific Officer at Advancis Pharmaceutical
Corporation, and lead the Boerhinger Ingelheim Departments of Virology and
About Affinium Pharmaceuticals, Inc.
Affinium Pharmaceuticals, Inc. is a pharmaceutical company focused on the
discovery, development and commercialization of novel anti-infective medicines
stemming from the bacterial fatty acid synthesis (FAS) II pathway. Affinium's
lead clinical development compound is the most potent small molecule
antibiotic in development for both oral and intravenous treatment of
staphylococcal infections including drug-resistant MRSA. This clinical
development candidate is scheduled for Phase I trials in 2007. Additionally,
Affinium uses its library of about 1,700 proprietary compounds and its
knowledge of fatty acid biosynthesis enzymes to develop additional novel
antibiotics to address a variety of therapeutic needs.
For further information:
For further information: Affinium Pharmaceuticals Owen G. Roberts, CFO,
416-645-6613 email@example.com www.afnm.com or Cook & Schmid Rick Cook,
619-814-2370 ext. 11 Cell: 619-987-3897 firstname.lastname@example.org